PT - JOURNAL ARTICLE AU - Gandrakota, Nikhila AU - Ramakrishnan, Manju AU - Sudireddy, Kavya AU - Shah, Megha K TI - Factors affecting Cost-Related Medication Non-Adherence among US population with Cardiovascular Risk Factors AID - 10.1101/2024.03.11.24304136 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.11.24304136 4099 - http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304136.short 4100 - http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304136.full AB - Introduction In the US, cardiovascular diseases (CVD) are the leading cause of death and disability. Cost-related non-adherence (CRMN) can have serious consequences and worsen CVD outcomes. We examined the relationship between CVD risk factors and CRMN among US adults.Methods CDC’s 2019-2021 National Health Interview Survey (NHIS) data was used to examine CRMN among adults, categorized into three groups based on reported risk factors. We used chi-square tests, logistic regression to determine factors associated with CRMN.Results Among 49,464 participants, young, unmarried individuals, females, less educated, and participants from South had higher CRMN than older, married individuals, males, and those with higher education residing in the other regions. Current smokers and those with more CVD risk factors also had a higher CRMN than former smokers and never-smokers. Conversely, those aged 65 or older, with high-income, and excellent self-rated health had lower CRMN than younger participants, low-income families, and those with poor self-health. Public insurance and Medicaid participants had lower CRMN than uninsured (OR 0.13, 95% CI, 0.04-0.45, and OR 0.24, 95% CI, 0.15-0.36). Stratified regression analysis by disease status, i.e., diabetes, hypertension, and hyperlipidemia, revealed participants with high-income had lower odds of CRMN (OR 0.38, 95% CI 0.28-0.50; OR 0.39, 95% CI, 0.28-0.58; OR 0.37, 95% CI 0.27-0.51 respectively) than those with lower incomes.Conclusion Adults under 65 with more CVD risk factors are at higher risk of CRMN. Hence, robust prescription drug coverage and targeted interventions are necessary to lower CRMN in those with CVD risk factors.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementMKS is supported in part by NIMHD (K23 MD015088-04) and Emory School of Medicine Doris Duke Charitable Foundation COVID-19 Fund to Retain Clinical Scientists and the Georgia CTSA (UL1-TR002378)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available dataset.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is openly available through CDCNHISNational Health Interview SurveyCDCCenters for Disease Control and PreventionNCHSNational Center for Health StatisticsCVDCardiovascular Disease